AnnuNovo

AnnuNovo is an early-stage medtech/regenerative medicine company developing a minimally invasive biomaterials-based treatment for spinal disc repair. Its lead product is an injectable, photo-crosslinked collagen gel designed to fill and seal annular defects after discectomy, with the goal of reducing reherniation and preserving disc structure. The technology was developed from Cornell and Weill Cornell research by Dr. Lawrence Bonassar and Dr. Roger Härtl, and the company was presented as a newly launched venture in 2026. Publicly available information indicates the program remains in preclinical development with supporting small- and large-animal data. AnnuNovo appears to be focused on spine care rather than a broad therapeutics pipeline.